+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of a commercial enzyme immunoassay for the detection of interferon gamma levels in active tuberculosis patients and vaccinated healthy subjects



Evaluation of a commercial enzyme immunoassay for the detection of interferon gamma levels in active tuberculosis patients and vaccinated healthy subjects



Mikrobiyoloji Bulteni 39(1): 73-77



The detection of plasma interferon gamma (IFN-g) levels has an important value for the evaluation of cell mediated immune response to Mycobacterium tuberculosis. The aim of this study was to investigate the plasma IFN-g levels by a commercial enzyme immunoassay (ELISA) and to compare the levels between recently diagnosed culture positive lung tuberculosis patients and BCG vaccinated healthy controls. Twenty-three patients with active lung tuberculosis (13 males, 10 females) and 34 BCG vaccinated healthy adults (16 male, 18 female) have been included in the study. The control subjects were questioned about passed tuberculosis infection and/or a contact with tuberculosis patients. No risk factors for exposure to M. tuberculosis were found in the control group. IFN-g levels were measured by QuantiFERON-TB (Cellestis, Australia) kit, and 22 of patients and 17 of control subjects were found to be positive. As a result, the sensitivity of QuantiFERON-TB test was high (95.6%), however its specificity was quite low (50%). In conclusion, QuantiFERON-TB may be used as a supplementary diagnostic test in patients considered to have active tuberculosis, before treatment. As BCG is in routine vaccination programme and the number of active tuberculosis cases is high in our country, this test seems to be invalid for the diagnosis of latent tuberculosis. Therefore, more specific tests that are not affected by the vaccine response, are required for the diagnosis of latent tuberculosis.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 048993315

Download citation: RISBibTeXText

PMID: 15900839


Related references

Noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for gamma 2-melanocyte-stimulating hormone (gamma 2-MSH) and measurement of immunoreactive gamma 2-MSH in plasma of healthy subjects. Journal of Clinical Laboratory Analysis 9(6): 397-406, 1995

A sandwich enzyme immunoassay for bovine interferon-gamma and its use for the detection of tuberculosis in cattle. Australian Veterinary Journal 67(4): 134-137, 1990

The diagnosis of bovine tuberculosis in Vaslui District by an enzyme immunoassay for detection of gamma-interferon. Revista Romana de Medicina Veterinara 14(3): 149-154, 2004

Evaluation of gamma interferon release assays using Mycobacterium tuberculosis antigens for diagnosis of latent and active tuberculosis in Mycobacterium bovis BCG-vaccinated populations. Clinical and Vaccine Immunology 17(12): 1985-1990, 2010

Evaluation of a gamma interferon enzyme immunoassay, a multiple-antigen ELISA, and an antigen 85 immunoassay for screening for Mycobacterium tuberculosis infection in orangutans (Pongo pygmaeus). Unknown, 2004

Development of a human gamma interferon enzyme immunoassay and comparison with tuberculin skin testing for detection of Mycobacterium tuberculosis infection. Clinical and Diagnostic Laboratory Immunology 5(4): 531-536, 1998

Advanced approach to activity evaluation for released-active forms of antibodies to interferon-gamma by enzyme-linked immunoassay. Journal of Immunoassay and Immunochemistry 40(3): 250-268, 2019

Novel approach to activity evaluation for release-active forms of anti-interferon-gamma antibodies based on enzyme-linked immunoassay. Plos one 9(5): E97017, 2014

Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. Bmc Infectious Diseases 9: 207, 2009

Evaluation of a Whole Blood Chemiluminescent Immunoassay of Interferon-gamma Inducible Protein 10 (IP-10) for Diagnosis of Tuberculosis Patients. Clinical Laboratory 62(1-2): 165-172, 2016

Diagnosis of active tuberculosis by enzyme-linked immunospot assay for interferon-gamma in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 53(4): 546-547, 2010

Diagnosis of latent tuberculosis infection in bacille Calmette-Guérin vaccinated subjects in China by interferon-gamma ELISpot assay. International Journal of Tuberculosis and Lung Disease 14(12): 1556-1563, 2010

Usefulness of whole-blood interferon-gamma assay and interferon-gamma enzyme-linked immunospot assay in the diagnosis of active pulmonary tuberculosis. Chest 132(3): 959-965, 2007

Evaluation of three commercial latex agglutination kits and a commercial enzyme immunoassay for the detection of cryptococcal antigen. Medical Mycology 47(3): 336-338, 2009

Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. Clinical Microbiology and Infection 16(8): 1282-1284, 2010